PUBLICATION
Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy
- Authors
- Arribat, Y., Mysiak, K.S., Lescouzères, L., Boizot, A., Ruiz, M., Rossel, M., Bomont, P.
- ID
- ZDB-PUB-190911-9
- Date
- 2019
- Source
- The Journal of Clinical Investigation 129(12): 5312-5326 (Journal)
- Registered Authors
- Arribat, Yoan, Bomont, Pascale, Mysiak, Karolina S., Rossel, Mireille
- Keywords
- Neurodevelopment, Neuromuscular disease, Neuroscience, Ubiquitin-proteosome system
- MeSH Terms
-
- Animals
- Cytoskeletal Proteins/genetics*
- Cytoskeletal Proteins/physiology
- Giant Axonal Neuropathy/etiology*
- Hedgehog Proteins/antagonists & inhibitors
- Hedgehog Proteins/physiology*
- Humans
- Mice
- Motor Neurons/physiology
- Muscles/innervation
- Mutation*
- NIH 3T3 Cells
- Patched-1 Receptor/physiology
- Signal Transduction
- Somites/physiology
- Zebrafish
- PubMed
- 31503551 Full text @ Journal of Clin. Invest.
Citation
Arribat, Y., Mysiak, K.S., Lescouzères, L., Boizot, A., Ruiz, M., Rossel, M., Bomont, P. (2019) Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy. The Journal of Clinical Investigation. 129(12):5312-5326.
Abstract
Growing evidence shows that alterations occurring at early developmental stages contribute to symptoms manifested in adulthood in the setting of neurodegenerative diseases. Here, we studied the molecular mechanisms causing giant axonal neuropathy (GAN), a severe neurodegenerative disease due to loss-of-function of the gigaxonin-E3 ligase. We showed that gigaxonin governs Sonic Hedgehog (Shh) induction, the developmental pathway patterning the dorso-ventral axis of the neural tube and muscles, by controlling the degradation of the Shh-bound Patched receptor. Similarly to Shh inhibition, repression of gigaxonin in zebrafish impaired motor neuron specification and somitogenesis and abolished neuromuscular junction formation and locomotion. Shh signaling was impaired in gigaxonin null zebrafish and was corrected by both pharmacological activation of the Shh pathway and human gigaxonin, pointing to an evolutionary-conserved mechanism regulating Shh signaling. Gigaxonin-dependent inhibition of Shh activation was also demonstrated in primary fibroblasts from GAN patients and in a Shh activity reporter line depleted in gigaxonin. Our findings establish gigaxonin as a key E3 ligase that positively controls the initiation of Shh transduction, reveal the causal role of Shh dysfunction in motor deficits, thus highlighting the developmental origin of GAN.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping